NCE-1 Intelligence & Market Opportunity

Jesduvroq

Daprodustat

Antianemic

Tablet

Jesduvroq is an oral HIF-PHI approved for the treatment of anemia in adults with chronic kidney disease on dialysis. It was voluntarily withdrawn in the U.S. for non-safety-related reasons but remains FDA-listed.

Approval Date

01-Feb-23

NCE-1 Date

01-Feb-27

NCE Date

01-Feb-28

Commercial snapshot

Market performance & projections

Revenue ($M)

100

CAGR (%)

23.68%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

174

2027

197

2028

221

2029

234

2030

236

2031

246

2032

258

Molecule profile

Details & specifications

Molecule

Daprodustat

Innovator

GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND

Dosage Form

Tablet

Strength

1 mg, 2 mg, 4 mg, 6 mg, 8 mg

Therapeutic Category

Antianemic

Usage

To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets